- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04045379
LASER and Radiofrequency and Genitourinary Syndrome of Menopause (EPMLARF-arm1)
LASER and Radiofrequency as Alternative Treatments for Genitourinary Syndrome of Menopause
Study Overview
Status
Intervention / Treatment
Detailed Description
Post menopause women with moderate or severe signs or symptoms of vulvovaginal atrophy will be eligible for the study.
The patients will be randomized to receive one of the three intravaginal therapies: LASER, Micro Ablative radiofrequency or Estriol. The applications will occur in the interval of 30 days for 3 times, for LASER and Radiofrequency groups. For the estriol group, the application will be done by the patient, daily for 2 weeks and them twice a week for 3 months, and each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube, to verify the correct use.
The follow-up visits will occur 30, 90, 180 and 360 days after the conclusion of the third month of treatment.
Will be evaluated: vulvar and vaginal histology before and after the use of LASER, radiofrequency or estriol; microbiota and vaginal pH before and after the use of LASER, radiofrequency or estriol; extracellular matrix and metalloproteinases in the remodeling of vulvovaginal collagen induced by estrogen, LASER and radiofrequency; quality of life, sexual dysfunctions and complaints before and after the use of LASER, radiofrequency or hormones; metabolomics and vaginal microbiome.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ana Maria HM Bianchi-Ferraro, PhD
- Phone Number: +5511995217431
- Email: anamariahmb@yahoo.com.br
Study Contact Backup
- Name: zsuzsanna IK Jarmy -di Bella, PhD
- Phone Number: +5511983490033
- Email: zsuvi@uol.com.br
Study Locations
-
-
SP
-
São Paulo, SP, Brazil, 0-4023- 062
- Federal University of Sao Paulo - Unifesp
-
Contact:
- Ana Maria HM Bianchi-Ferraro, PhD
- Phone Number: +5511995217431
- Email: anamariahmb@yahoo.com.br
-
Contact:
- Zsuzsanna IK Jarmy-di Bella, PhD
- Phone Number: +5511983490033
- Email: zsuvi@uol.com.br
-
Sub-Investigator:
- Marair FG Sartori, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women between 2 and 5 years after menopause, without hormone therapy for at least 2 years
To present, at least moderate, or severe intensity (score 4 or more of visual analog scale ( 0-10)) of one of the signs or symptoms of of vulvovaginal atrophy:
- Burning
- Discomfort
- Dryness
- Cracks
- Pruritus
- Lack of vaginal lubrication
- Penetration dyspareunia that began at the menopausal or postmenopausal transition
- Decreased vaginal epithelium turgor and trophism
- Deletion of mucous and skin folds.
The Exclusion criteria will be:
- Active genital infection, active infection of HPV (human papillomavirus) or Herpes, users of medications with estrogenic effect (digoxin, tamoxifen and other chemicals)
- Postmenopausal genital bleeding, uncontrolled diabetes, use of multivitamins with zinc, use of copper or hormonal IUDs (intrauterine device) at the time of inclusion, presence of genitourinary or rectovaginal fistulas.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: LASER
The patients will receive 3 consecutive applications of intravaginal and vulvar CO2 (carbon dioxide)LASER, according to the manufacturer protocol for vaginal atrophy.
The applications will be separated by the interval of 30 days
|
Use of the SmartXide Touch V²LR, Co2 Laser System to perform ambulatory intravaginal and vulvar application of LASER, to postmenopausal genitourinary syndrome.
The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
Other Names:
|
Active Comparator: Micro Ablative Radiofrequency
The patients will receive 3 consecutive applications of intravaginal and vulvar MIcro ablative radiofrequency, according to the manufacturer protocol for vaginal atrophy.
The applications will be separated by the interval of 30 days
|
Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome.
The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured.
Other Names:
|
Active Comparator: Estriol
The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months .
Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.
|
The patient will perform self application of this vaginal estriol daily for 2 weeks and after that the applications will occur twice a week.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Improvement of signs and symptoms postmenopausal genitourinary syndrome with intravaginal LASER, Microablative Radiofrequency, and topic estriol
Time Frame: The evaluation will be done 180 days after treatment
|
Will be applied a Visual Analogic Scale (0-10) to access the improvement of genitourinary signs and symptoms, the results of the three groups will be compared
|
The evaluation will be done 180 days after treatment
|
Satisfaction of postmenopausal women with genitourinary syndrome with the treatment by intravaginal LASER, Micro ablative Radiofrequency, and topic estriol
Time Frame: The evaluation will be done 180 days after treatment
|
Will be applied a LIKERT Satisfaction Scale (1-5) to access the satisfaction with the treatment, the results of the three groups will be compared
|
The evaluation will be done 180 days after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of Microbiota before and after the use of intravaginal LASER, Micro Ablative radiofrequency or topic estriol.
Time Frame: The evaluation will occur pre treatment 30, 90 , 180 and 360 days after treatment
|
The vaginal flora will be evaluated by vaginal smear.
The results of the three groups will be compared
|
The evaluation will occur pre treatment 30, 90 , 180 and 360 days after treatment
|
Evaluation of vaginal pH before and after the use of intravaginal LASER, Micro ablative radiofrequency or topic estriol.
Time Frame: The evaluation will occur pre treatment and 30, 90, 180 and 360 days after treatment
|
The vaginal pH will be verified by the use of pH tape's .The results of the three groups will be compared
|
The evaluation will occur pre treatment and 30, 90, 180 and 360 days after treatment
|
Histologic evaluation of vagina and vulva before and after the use of intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic estriol.
Time Frame: The evaluation will occur pre treatment and 30 days after treatment
|
Thickness of epithelium (mm and number of layers), and evaluation of expression of Ki-67 and VEGF (vascular endothelial growth factor) will be done on vaginal and vulvar biopsies.The results of the three groups will be compared
|
The evaluation will occur pre treatment and 30 days after treatment
|
Evaluation of impact in Quality of life after treatment with intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic estriol.
Time Frame: The evaluation will occur pre treatment and 30 days after treatment
|
The IQol (incontinence quality of life questionnaire, validated to portuguese language - score 0-100) will be used to evaluate quality of life .The results of the three groups will be compared
|
The evaluation will occur pre treatment and 30 days after treatment
|
Evaluation of impact in Sexual function after treatment with intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic estriol.
Time Frame: The evaluation will occur pre treatment and 30 days after treatment
|
The FSF-I(Female Sexual Function Index , validated to portuguese language- score range from 2 - 36) will be used to evaluate sexual function .
The results of the three groups will be compared
|
The evaluation will occur pre treatment and 30 days after treatment
|
Evaluation of extracellular matrix before and after the use of intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic estriol.
Time Frame: The evaluation will occur pre treatment and 30 days after treatment
|
Evaluation of the composition and concentration of the glycosaminoglycans of extracellular matrix in the vaginal and vulvar biopsies by specific markers.
The results of the three groups will be compared
|
The evaluation will occur pre treatment and 30 days after treatment
|
Evaluation of matrix metalloproteinases(MMP) in remodeling of vulvovaginal collagen induced by intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic estriol.
Time Frame: The evaluation will occur pre treatment and 30 days after treatment
|
Evaluation of the tissue distribution of the MMP-1, MMP-2, MMP-3, MMP-7, MMP-9 metalloproteinases of collagen I, II, IV and elastin proteins by specific markers on vaginal and vulvar biopsies.
The results of the three groups will be compared
|
The evaluation will occur pre treatment and 30 days after treatment
|
Evaluation of visual aspect of vulva after the use of intravaginal and vulvar LASER, Micro Ablative radiofrequency or topic estriol.
Time Frame: The pictures will be taken before and 30 days and 180 days after treatment.
|
Pictures of vulva will be taken before and after treatment.
The images will be evaluated by a blind gynecologist and dermatologist regarding the type of treatment and the chronological order of the photos, which will classify the images as: better; equal or worse, in relation to tropism and number of vulvar skin grooves, The results of the three groups will be compared
|
The pictures will be taken before and 30 days and 180 days after treatment.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Zsuzsanna IK Jarmy - di Bella, PhD, professor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CEP0431/2018 arm 1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Genitourinary Symptoms
-
National Yang Ming UniversityNational Science Council, TaiwanCompletedGenitourinary Symptoms
-
Żelazna Medical Centre, LLCLaboratory of Genetics and Human Genomics, University of GdańskCompleted
-
59th Medical WingCompletedGenitourinary SymptomsUnited States
-
University of California, IrvineRecruitingGenitourinary Syndrome of MenopauseUnited States
-
Michigan Institution of Women's Health PCCompletedGenitourinary Syndrome of MenopauseUnited States
-
Duke UniversityWallace H. Coulter FoundationCompletedCancer of the Gastrointestinal, Genitourinary or Gynecologic SystemsUnited States
-
Quanta System, S.p.A.Unknown
-
Stratpharma AGRecruitingGenitourinary Syndrome of MenopauseUnited States
-
EgymedicalpediaCompleted
-
Maltepe UniversityCompletedGenitourinary Syndrome of MenopauseTurkey
Clinical Trials on LASER
-
Manchester University NHS Foundation TrustTopcon Corporation; Optos, PLCWithdrawnDiabetic Macular OedemaUnited Kingdom
-
University of Sao Paulo General HospitalCompletedOsteoarthritisBrazil
-
Mashhad University of Medical SciencesUnknownTemporomandibular Joint Disorder
-
State University of Minas GeraisFundação de Amparo à Pesquisa do estado de Minas GeraisActive, not recruiting
-
Universidade Norte do ParanáUniversidade Estadual de LondrinaCompletedPerformance | Aged | Muscle Strength | Resistance Training | LasersBrazil
-
Northwestern UniversityEnrolling by invitation
-
Universidade Estadual Paulista Júlio de Mesquita...Completed
-
Federal University of Health Science of Porto AlegreUnknown
-
Montefiore Medical CenterNot yet recruitingHidradenitis Suppurativa | ScarringUnited States
-
Odense University HospitalMoorfields Eye Hospital NHS Foundation Trust; University of Southern Denmark; Yamagata University and other collaboratorsCompletedProliferative Diabetic RetinopathyDenmark